At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ENGN ENGENE HOLDINGS INC
Post-Mkt 01-30 19:48:15 EST
9.53
-0.74
-7.21%
盘后9.72
+0.19+1.99%
19:30 EST
High11.38Low9.51Vol302.54K
Open10.94D1 Closing10.27Amplitude18.21%
Mkt Cap638.36MTradable Cap355.78MTotal Shares66.98M
T/O3.03MT/O Rate0.81%Tradable Shares37.33M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Jefferies Initiates Coverage on enGene With Buy Rating, $28 Price Target
MT Newswires Live  ·  01-30 20:29
Jefferies Initiates Coverage on enGene With Buy Rating, $28 Price Target
enGene initiated with a Buy at Jefferies
TIPRANKS  ·  01-30 18:00
enGene initiated with a Buy at Jefferies
enGene Holdings Issues 2026 Warrants to Purchase Common Shares
Reuters  ·  01-22
enGene Holdings Issues 2026 Warrants to Purchase Common Shares
enGene Holdings - Secures up to $100 Mln for Detalimogene Development & Commercialization for Bladder Cancer
THOMSON REUTERS  ·  01-21
enGene Holdings - Secures up to $100 Mln for Detalimogene Development & Commercialization for Bladder Cancer
enGene Announces Expanded $125 Million Debt Facility With Hercules Capital, Inc.
THOMSON REUTERS  ·  01-21
enGene Announces Expanded $125 Million Debt Facility With Hercules Capital, Inc.
enGene Secures Expanded $125 Million Debt Facility from Hercules Capital
Reuters  ·  01-21
enGene Secures Expanded $125 Million Debt Facility from Hercules Capital
EnGene Fiscal 2025 Loss Widens
MT Newswires Live  ·  2025-12-23
EnGene Fiscal 2025 Loss Widens
enGene Holdings Q4 EPS $(0.73) Misses $(0.57) Estimate
Benzinga  ·  2025-12-23
enGene Holdings Q4 EPS $(0.73) Misses $(0.57) Estimate
enGene reports FY net loss of USD 117.3 million, more than double year-on-year
Reuters  ·  2025-12-23
enGene reports FY net loss of USD 117.3 million, more than double year-on-year
enGene Holdings Inc - Cash and Marketable Securities Plus Proceeds From Nov Financing Expected to Provide Cash Runway Into 2H 2028
THOMSON REUTERS  ·  2025-12-23
enGene Holdings Inc - Cash and Marketable Securities Plus Proceeds From Nov Financing Expected to Provide Cash Runway Into 2H 2028
Press Release: enGene Reports Full Year 2025 Financial Results and Provides Business Update
Dow Jones  ·  2025-12-23
Press Release: enGene Reports Full Year 2025 Financial Results and Provides Business Update
EnGene Says US FDA Selects Detalimogene for Manufacturing Pilot Program
MT Newswires Live  ·  2025-12-02
EnGene Says US FDA Selects Detalimogene for Manufacturing Pilot Program
BRIEF-Engene’S Detalimogene Selected For FDA Manufacturing Pilot Program To Support Manufacturing Readiness
Reuters  ·  2025-12-02
BRIEF-Engene’S Detalimogene Selected For FDA Manufacturing Pilot Program To Support Manufacturing Readiness
enGene Reports 62% Complete Response Rate for Detalimogene in Bladder Cancer Trial
Reuters  ·  2025-12-02
enGene Reports 62% Complete Response Rate for Detalimogene in Bladder Cancer Trial
enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness
THOMSON REUTERS  ·  2025-12-02
enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness
enGene Holdings - FDA Selects Detalimogene Voraplasmid to Participate in Chemistry, Manufacturing, & Controls Development & Readiness Pilot Pprogram
THOMSON REUTERS  ·  2025-12-02
enGene Holdings - FDA Selects Detalimogene Voraplasmid to Participate in Chemistry, Manufacturing, & Controls Development & Readiness Pilot Pprogram
enGene Holdings Inc. to Present at Piper Sandler 37th Annual Healthcare Conference
Reuters  ·  2025-11-25
enGene Holdings Inc. to Present at Piper Sandler 37th Annual Healthcare Conference
enGene Holdings Files For Offering Of Common Shares, Size Not Disclosed - SEC Filing
Reuters  ·  2025-11-20
enGene Holdings Files For Offering Of Common Shares, Size Not Disclosed - SEC Filing
enGene Holdings Inc : Leerink Partners Cuts Target Price to $19 From $21
THOMSON REUTERS  ·  2025-11-14
enGene Holdings Inc : Leerink Partners Cuts Target Price to $19 From $21
enGene Holdings (ENGN) Valuation in Focus Following Promising Phase 2 Bladder Cancer Trial Results
Simply Wall St.  ·  2025-11-14
enGene Holdings (ENGN) Valuation in Focus Following Promising Phase 2 Bladder Cancer Trial Results

Introduction

Company Name.
ENGENE HOLDINGS INC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Issue price:
--